Michael Schmidt Analyst Performance

Senior Biotech Analyst at Guggenheim

Michael Schmidt is a stock analyst at Guggenheim focused in the medical sector, covering 43 publicly traded companies. Over the past year, Michael Schmidt has issued 43 stock ratings, including buy and hold recommendations. While full access to Michael Schmidt's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Michael Schmidt's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 132 Last 10 Years
Buy Recommendations: 86.82% 112 Buy Ratings
Companies Covered: 43 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	86.8%	112 ratings
Hold	13.2%	17 ratings
Sell	0.0%	0 ratings

Out of 129 total stock ratings issued by Michael Schmidt at Guggenheim, the majority (86.8%) have been Buy recommendations, followed by 13.2% Hold.

Best & Worst Calls

Best Call
0000.0%
EXEL
May 2016
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
DARE
Jun 2016
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	97.7% of companies on NASDAQ	42 companies
NYSE	2.3% of companies on NYSE	1 company

Michael Schmidt, an analyst at Guggenheim, currently covers 43 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 41 companies	95.3%
	Miscellaneous 1 company	2.3%
	Energy 1 company	2.3%

Michael Schmidt of Guggenheim specializes in stock coverage within the Medical sector, with additional focus on and Energy companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 25 companies	58.1%
PHARMACEUTICAL PREPARATIONS 7 companies	16.3%
MED - DRUGS 6 companies	14.0%
BIOTECHNOLOGY 2 companies	4.7%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	2.3%
Miscellaneous 1 company	2.3%
SOLAR 1 company	2.3%

About Michael Schmidt

Dr. Schmidt is a Senior Managing Director and Equity Research Analyst covering the Biotechnology sector based in Guggenheim’s Boston office. With over 17 years of Wall Street experience, Dr. Schmidt joined Guggenheim from Leerink Partners in 2018 where he was a Senior Biotechnology Research Analyst. Previously, he was a healthcare analyst and consultant at Susquehanna International Group’s private equity team in San Francisco and a research fellow at Harvard University. Dr. Schmidt earned his M.S. in Biology and Ph.D. in Biochemistry at the University of Stuttgart, Germany. Dr. Schmidt was named runner-up in the 2017 Institutional Investor All-America Research Survey, Biotechnology/Mid- & Small-Cap.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
IMNM Immunome	8/25/2025	Reiterated Rating	$10.49	$25.00	Buy
MRSN Mersana Therapeutics	8/14/2025	Lower Price Target	$6.96	$30.00	Buy
ADCT ADC Therapeutics	8/13/2025	Reiterated Rating	$3.08	$10.00	Buy
ORIC Oric Pharmaceuticals	8/13/2025	Reiterated Rating	$10.01	$18.00	Buy
CMPX Compass Therapeutics	8/12/2025	Boost Price Target	$3.34	$12.00	Buy
ONC BeOne Medicines	8/7/2025	Boost Price Target	$296.33	$365.00	Buy
ARVN Arvinas	8/7/2025	Lower Price Target	$6.19	$15.00	Buy
TNGX Tango Therapeutics	8/6/2025	Boost Price Target	$6.35	$10.00	Buy
COGT Cogent Biosciences	7/8/2025	Reiterated Rating	$9.16	$17.00	Buy
RVMD Revolution Medicines	6/25/2025	Reiterated Rating	$39.18	$80.00	Buy
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
ADCT ADC Therapeutics	6/13/2025	Reiterated Rating	$3.77	$10.00	Buy
KYMR Kymera Therapeutics	6/3/2025	Reiterated Rating	$49.69	$60.00	Buy
URGN Urogen Pharma	5/23/2025	Lower Price Target	$3.93	$15.00	Buy
MRSN Mersana Therapeutics	5/16/2025	Reiterated Rating	$8.20	$125.00	Buy
EXEL Exelixis	5/15/2025	Set Price Target	$45.40	$45.00	Buy
ERAS Erasca	5/14/2025	Set Price Target	$1.29	$3.00	Buy
KYMR Kymera Therapeutics	5/12/2025	Reiterated Rating	$31.92	$52.00	Buy
RVMD Revolution Medicines	5/8/2025	Lower Price Target	$42.50	$80.00	Buy
ONC BeOne Medicines	5/8/2025	Boost Price Target	$233.78	$350.00	Buy
RLAY Relay Therapeutics	5/7/2025	Lower Price Target	$3.03	$10.00	Buy
SNDX Syndax Pharmaceuticals	5/6/2025	Reiterated Rating	$12.16	$32.00	Buy
ARVN Arvinas	5/2/2025	Lower Price Target	$7.00	$16.00	Buy
SWTX SpringWorks Therapeutics	4/28/2025	Downgrade	$46.18	$47.00	Neutral
ONC BeOne Medicines	4/16/2025	Reiterated Rating	$234.88		Buy
ONC BeOne Medicines	4/10/2025	Reiterated Rating	$211.15	$348.00	Buy
NBTX Nanobiotix	4/4/2025	Lower Price Target	$3.27	$8.00	Buy
ADCT ADC Therapeutics	3/31/2025	Lower Price Target	$1.34	$7.00	Buy
MRUS Merus	3/28/2025	Reiterated Rating	$44.63	$109.00	Buy
ADAP Adaptimmune Therapeutics	3/26/2025	Lower Price Target	$0.25	$1.75	Buy
IMNM Immunome	3/20/2025	Lower Price Target	$8.47	$25.00	Buy
INCY Incyte	3/18/2025	Downgrade	$62.01	$92.00	Neutral
MRUS Merus	3/18/2025	Reiterated Rating	$46.94	$109.00	Buy
ARVN Arvinas	3/13/2025	Lower Price Target	$8.52	$32.00	Buy
LEGN Legend Biotech	3/12/2025	Reiterated Rating	$37.63		Neutral
AVBP ArriVent BioPharma	3/10/2025	Initiated Coverage	$21.87	$45.00	Buy
ORIC Oric Pharmaceuticals	2/26/2025	Reiterated Rating	$8.69		Buy
CMPX Compass Therapeutics	2/24/2025	Initiated Coverage	$2.92	$12.00	Buy
EXEL Exelixis	2/12/2025	Reiterated Rating	$35.11	$42.00	Buy
ARVN Arvinas	2/12/2025	Reiterated Rating	$18.83	$57.00	Buy
MRUS Merus	2/12/2025	Reiterated Rating	$40.02		Buy

ORIC Oric Pharmaceuticals	2/10/2025	Reiterated Rating	$12.25		Buy
IPSC Century Therapeutics	1/22/2025	Reiterated Rating	$0.90		Buy
EXEL Exelixis	1/22/2025	Reiterated Rating	$33.97		Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.